Generic Copaxone is coming

Share this article:

Teva's push to keep generic Copaxone off the market its over. Bloomberg reports the company lost its suit to keep generics at bay, just 10 days before the expiration of the branded MS drug's patent.

Teva wanted more testing of generic versions of the drug, but a federal judge said forget it.

The company has prepped investors for the possibility that its major drug could get competition this year, and even went so far as to provide two 2014 forecasts: one in which Copaxone had the market to itself, and other in which it did not.

Despite generics concern, the company has been able to convert Copaxone users to a newer, patent-protected formulation.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Imbruvica lassoes CLL indication

The FDA slapped a Breakthrough Therapy label on the CLL indication pursuit in February.

FDA asks social media "how'm I doin?"

The FDA's Center for Drug Evaluation and Research's Office of Communications wants a system that will help assess its messaging reach across the interwebs and its many forums.

Reckitt Benckiser wants out of pharma

The company plans to spin off its pharmaceutical unit.